Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 1Colorectal Neoplasms 1

Interventions

Dexamethasone 169Bortezomib 92Lenalidomide 85daratumumab 44Thalidomide 44pomalidomide 43Melphalan 40Cyclophosphamide 33carfilzomib 29Calcium Dobesilate 27Prednisone 19Doxorubicin 16elotuzumab 14isatuximab 12Filgrastim 12ixazomib 11Vincristine 10Peripheral Blood Stem Cell Transplantation 10belantamab mafodotin 9Granulocyte Colony-Stimulating Factor 9Zoledronic Acid 8selinexor 7dexamethasone acetate 7Epoetin Alfa 7Etoposide 6fludarabine 5Cisplatin 5Carmustine 5iberdomide 4Radiotherapy 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Multiple Myeloma × perifosine × Clear all
NCT01002248 2018-02-09

Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients

AEterna Zentaris

Phase 3 Terminated
135 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡